

YEAR-END REPORT

Fourth quarter, 2021



This English translation of the original document is for convenience purposes only. In the event of any discrepancy between the Swedish version and the English translation, the Swedish version shall take precedence.

Fourth quarter, 2021

Financial summary

Numbers in () indicate the corresponding period from the previous year.

- » Revenues for the quarter amounted to SEK 21.0 million (8.9). Total revenues up to and including the fourth quarter amounted to SEK 81.8 million (29.3), which is growth of 179% for the entire year.
- » Operating result was SEK -25.7 million (-12.3). Total operating result was SEK -78.0 million up to and including the fourth quarter (-43.1).
- » The Group's result after financial items was SEK -26.5 million (-12.5).
- » Earnings per share attributable to the shareholders of the Parent Company totaled SEK -0.44 (-0.21).
- » Equity on the balance sheet date was SEK 142.6 million (201.9) or SEK 1.89 per share (3.43).
- » Debt/equity ratio was 60% (83%) on the balance sheet date.
- » Cash flows from operating activities amounted to SEK -31.5 million (-22.3).
- » On the balance sheet date, the Group's cash and cash equivalents totaled SEK 28.6 million (151.9).

Significant events in the period

- » November 29, 2021 | The Board of Directors of Cell Impact has resolved on a fully guaranteed rights issue of up to approximately SEK 349 million
The Board of Directors of Cell Impact AB, pursuant to the authorization granted by the extraordinary general meeting held on November 16, 2021, resolved on a fully guaranteed rights issue of up to 16,812,094 B-shares with a maximum of SEK 348.9 million before issue expenses.
- » December 27, 2021 | Cell Impact announces final outcome of fully guaranteed rights issue
Cell Impact announced the outcome of the rights issue for which the subscription period ended on December 23, 2021. The issue increased Cell Impact's share capital by SEK 1,946,103 to SEK 8,757,466. The number of B-shares rose by 16,812,094 to 75,436,628, which increased the total number of A and B-shares to 75,654,428 when the issue was registered with the Swedish Companies Registration Office in January 2022. The rights issue, which was completed in January 2022, provided the company with approximately SEK 348.9 million before issue expenses of SEK 45.3 million.

Significant events after the period

- » There were no significant events after the reporting period.

CEO'S MESSAGE

Growing sales

During the final quarter of 2021, Cell Impact achieved sales of SEK 21.0 million, which is SEK 12.1 million (+136 percent) higher than the corresponding quarter last year. Our operating result amounted to SEK -25.7 million, compared with SEK -12.3 million during the corresponding quarter in 2020. The negative operating result is due to the significant investments for growth that are now taking place in premises, equipment and personnel.

For the full year 2021, the company's sales amounted to SEK 81.8 million, an increase of 179 percent compared with 2020 when sales totaled SEK 29.3 million. The operating result for the full year amounted to SEK -78.0 million compared with SEK -43.1 million in 2020. This result was in part burdened by cost increases for transport and equipment installations triggered by the Covid-19 pandemic.

A growing order book

During the quarter, the company's orders for flow plates scheduled for delivery in 2022 grew. We are entering the new year with a robust order book that involves a significant part of Cell Impact's production capacity this year. The order book also includes a number of innovative tool projects for new flow plates for prototype series.

This is extremely gratifying and testament to the hard work put in by everyone in the organization.

At the beginning of 2021, we faced a situation where demand exceeded our production capacity. But after building up capacity, we're catching up and have achieved a better balance. Today, we have surplus capacity as demand currently looks, making it possible for us to satisfy additional demand from current and prospective customers relatively quickly.

The Covid-19 pandemic, however, still presents challenges for global raw material supplies. And for Cell Impact, the availability of stainless steel is crucial. For this reason, we have now established a supply model that secures our need for raw materials on a rolling 12-month basis. This will enable us to grow and maintain a high level of deliveries for the needs of both existing and future customers.

We also face other important purchasing and delivery issues where it can be said that our international organization plays an important role in supporting our purchasing activities through its local presence.

The first delivery of production equipment to Plug Power went as planned during the fourth quarter, although the pandemic sometimes tried to throw a wrench in the works. Due to travel restrictions, we have been forced to carry out acceptance tests digitally and

traditional factory meetings have been replaced by video conferencing. The last delivery of equipment is somewhat delayed and will take place during the first quarter of 2022.

Greater production capacity

During the fourth quarter, we began using the new capacity we installed during the summer in its entirety. Capacity building is continuing with equipment being installed during the quarter, albeit at a slightly slower pace.

As part of our Phase II project, we have started renovating an additional 2,500 m² of factory space – a doubling of our current production premises. This area will be gradually put into use during 2022. In addition to increasing capacity to meet growing demand, the project also includes significant process development to reduce production costs and new processes to broaden our offering.

At the end of the fourth quarter, the company had 106 employees after a number of successful recruitment campaigns during the year. With our green, high-tech profile, Cell Impact is perceived as a very attractive employer.

I'll conclude as usual with some of the latest news from the growing hydrogen industry:

» Daimler, along with NextEra Energy Resources and Blackrock Renewable Power, has initially invested USD 650 million in building hydrogen and battery charging stations for trucks in North America.

[Read more >](#)

» Despite the pandemic, 2021 was a record year for the expansion of hydrogen refueling stations with 142 new stations being added, 89 of which are in Asia. Globally, there are now 685 hydrogen refueling stations, including 228 places to refuel in Europe.

[Read more >](#)

» Toyota announced that it will open a new production facility outside Brussels for its latest version of compact fuel cells. They will also offer help to vehicle manufacturers who want to integrate fuel cell technology in electric vehicles.

[Read more >](#)

» One of the world's largest truck manufacturers, Hyzon Motors, has opened the doors to its new European headquarters and center for hydrogen-powered trucks in Groningen, the Netherlands.


[Read more >](#)

- » Interest in hydrogen is growing in the aviation industry. In addition to large companies such as Airbus, there are many smaller start-ups now developing technology for emission-free air travel.
[Here's the full list if you'd like to read more >](#)
- » With hydrogen as a growing global energy source, concern about how it could impact global security is also increasing. A new report from IRENA (International Renewable Energy Agency) addresses hydrogen from a security policy perspective.
[Read more >](#)
- » Many people are trying to predict the future now that hydrogen is definitely on its way to becoming a new global energy source. A recent report from PwC and the World Energy Council summarizes where we're headed.
[Read more >](#)

- » Finally, good news for anyone who loves electric racing! Extreme-E is so pleased with their hydrogen generators that they announced they will continue to use fuel cell technology to charge their electric cars in the desert in 2022. Great for the environment and for those of us who like fast electric cars!

[Read more >](#)

Pär Teike, CEO
Karlskoga, February 2022



Financial performance in summary

Amounts in SEK million	2021	2020	2021	2020
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Revenue	21.0	8.9	81.8	29.3
Operating profit/loss	-25.7	-12.3	-78.0	-43.1
Profit/loss before tax	-26.5	-12.5	-79.7	-44.3
Profit/loss after tax, attributable to the shareholders of the Parent Company	-26.6	-12.5	-79.9	-44.3
Cash flows from operating activities	-31.5	-22.3	-86.1	-47.6
Earnings per share before and after dilution (SEK)	-0.44	-0.21	-1.35	-0.88

	2021/12/31	2020/12/31
Cash and cash equivalents on the balance sheet date	28.6	151.9
Debt/equity ratio at end of period (%) ¹⁾	60%	83%
Equity/share	1.89	3.43

1) Debt/equity ratio, equity as a percentage of total assets

Revenue

The Group's revenues for the quarter (which are the same as those of the Parent Company) amounted to SEK 21.0 million (8.9), which is growth of 136 percent compared with the previous year. Revenues during the quarter refer to the completion of orders received during 2021 and new orders received during the quarter.

Total revenues up to and including the fourth quarter amounted to SEK 81.8 million (29.3), which is growth of 179 percent for the entire year.

Performance

The Group's operating loss for the period was SEK -25.7 million (-12.3). The total operating loss was SEK -78.0 million up to and including the fourth quarter (-43.1). Increased purchases of goods and services as well as personnel costs are the main reason for the company's higher costs.

Other information

Financial position

Since the turn of the year in 2020, equity decreased from SEK 201.9 million to SEK 142.6 million in 2021. The decrease is chiefly related to higher operating costs and production-related investments.

Funding and liquidity

Cash flows from operating activities before the change in working capital totaled SEK -23.2 million during the quarter, which was primarily due to the loss made in the period.

Investments of SEK 16.3 million aimed at improving Cell Impact's production process and adaptations of new premises were made during the period. In the fourth quarter 2021, SEK 0.5 million of the company's non-current liabilities was repaid, which as at December 31, 2021 totaled SEK 3.9 million (excluding lease liabilities). The company's cash and cash equivalents decreased by SEK 28.9 million during the quarter from SEK 57.5 million as at September 30, 2021 to SEK 28.6 million as at December 31, 2021, mainly as a result of higher operating costs and production-related investments.

In December, the company carried out a rights issue that was completed in January 2022 and that contributed SEK 348.9 million to the company excluding issue expenses of approximately SEK 45.3 million. Issues that were decided during the year but were completed after the end of the financial year are only reported by the Parent Company, as according to the Parent Company's reporting standards, issues are regarded as completed as at the subscription date. Compared with the Parent Company, cash issues in the Group are not considered to be completed until the proceeds from the issue have been paid in, in accordance with IFRS. Only SEK 20.0 million of the proceeds from the issue had been paid in as at the balance sheet date. For more information, see Note 3.

As at December 31, cash and cash equivalents totaled SEK 28.6 million (151.9). On the balance sheet date, cash and cash equivalents did not include proceeds from the issue that the company received in January 2022. Pro forma cash and cash equivalents, including proceeds from the issue and deductions for issue expenses amounted to SEK 314.8 million.

Employees

Payroll expenses totaled SEK -19.7 million (-8.9) during the quarter. The total number of employees was 106 (36) at the end of the quarter.

Staff costs in relation to the comparison period are attributable to Cell Impact employing more people during the period.

Parent Company

As the operations of the Parent Company essentially correspond to those of the Group, comments for the Group as a whole also apply to the Parent Company.

In the Parent Company, cash issues are reported at subscription compared with the Group, where they are reported when issue proceeds are paid in. For more information, see Note 3.

Share capital

The number of registered A-shares in Cell Impact is 217,800 and the number of registered B-shares is 58,624,534. The total number of votes in the company amounts to 6,080,253, as the A-shares confer a right to one vote per share while the B-shares confer a right to 1/10 vote per share. The total number of shares in Cell Impact, including both A and B-shares, is 58,842,334 shares. The company's registered share capital was SEK 6,811,362 as at December 31, 2021. The shares have a quota value of approximately 0.12 SEK.

When the rights issue was carried out in December, an additional 16,812,094 shares were subscribed for, corresponding to share capital of SEK 1,946,103. The shares were registered by the Swedish Companies Registration Office in January 2022 and are reported as subscribed but not registered share capital in the balance sheet as at December 31, 2021.

After the balance sheet date, December 31, 2021, at the request of the A-shareholders, all A-shares in Cell Impact were converted into B-shares. Cell Impact now has only B-shares, where all 75,654,428 shares in the company now carry the same voting rights.

Transactions between related parties

Cell Impact did not purchase any services from related parties during the period.

Risks and uncertainties

Risk and uncertainties were reported in the investor prospectus that was prepared in connection with the rights issue in 2021 and which is available at cellimpact.com.

Estimates and judgments

The preparation of Cell Impact's consolidated accounts required a number of estimates and judgments to be made, which may affect the value of assets, liabilities and provisions that were reported at the time when the accounts were closed. In addition, the recognized value of expenses during the reporting periods may also be affected. Estimates and judgments are evaluated continually and are based on historic experience and other factors, including expectations of future events that are considered to be reasonable under current conditions.

Going concern

As previously announced by the company's Board of Directors, Cell Impact received a contribution of SEK 349 million before issue expenses in a rights issue. The purpose of the rights issue is to ensure continued financing of Cell Impact's business plan, which includes increasing the company's production capacity. Consequently, the net proceeds will be used to finance the company's existing day-to-day operations, investments in preparing additional production space and in new production equipment to ensure increased production capacity and capabilities as well as for other business purposes. Together with existing cash, proceeds from the issue are expected to be sufficient to finance the company's business plan until the middle of 2023.

Update regarding Covid-19 pandemic

Cell Impact has been impacted to varying degrees by the ongoing pandemic, which has generally meant slightly lower levels of activity among the company's subcontractors and customers alike. During the pandemic, the company has focused on employee health and has continued to implement measures to reduce the risk of the spread of infection. In addition, the global shortage of components and transportation

has meant that Cell Impact has experienced longer delivery times for certain types of mechanical equipment.

Since the beginning of 2022, however, there has been a significant improvement with clear positive signals from both customers and suppliers, primarily in Europe and North America. Strict restrictions are still in place in many Asian countries, but the company expects these to be eased in the near future as long as nothing unforeseen happens. Even though at the time of writing the company is experiencing higher than normal sickness absences as a result of Covid-19 and related issues, Cell Impact has an overall positive view for 2022 with good conditions for positive sales development and a significant increase in sales activities.

Cell Impact is continuing to follow developments as the pandemic continues and adheres to the recommendations of authorities to limit the spread of Covid-19.

Disputes

At the moment, Cell Impact is involved in one ongoing dispute. The background is that in 2019, Nasdaq First North Growth Market in Stockholm reported Cell Impact to the Disciplinary Committee of Nasdaq Stockholm because when communicating to the market, the company failed to mention the name of a customer in an order. The Disciplinary Committee of Nasdaq Stockholm accepted Cell Impact's explanation; however, the Financial Supervisory Authority has subsequently notified Cell Impact that it may investigate the matter in addition to the investigation carried out by the Disciplinary Committee of Nasdaq Stockholm. It is Cell Impact's assessment that the Financial Supervisory Authority is awaiting a ruling on a similar issue in the administrative court for guidance for possible action.

Financial statements

Summary consolidated income statement

Amounts in SEK million	Note	2021	2020	2021	2020
		Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Revenue	2	21.0	8.9	81.8	29.3
Purchase of products and services		-14.3	-3.2	-46.9	-10.2
Other external costs		-9.6	-7.0	-40.3	-26.4
Staff costs		-19.7	-8.9	-62.4	-28.9
Depreciation and amortization		-2.9	-2.0	-10.2	-6.7
Other operating costs		-0.1	-0.1	-0.0	-0.2
Operating result		-25.7	-12.3	-78.0	-43.1
Net finance income		-0.8	-0.4	-1.7	-1.2
Profit/loss before tax		-26.5	-12.5	-79.7	-44.3
Tax		-0.1	-	-0.1	-
Profit/loss attributable to the shareholders of the Parent Company		-26.6	-12.5	-79.9	-44.3

Earnings per weighted number of shares, before and after dilution

Amount in SEK million	Note	2021	2020	2021	2020
		Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Average number of ordinary shares outstanding		60,304,255	58,385,812	59,210,818	50,324,244
Total number of shares at the end of the period	3	75,654,428	58,842,334	75,654,428	58,842,334
Earnings per weighted number of shares, before and after dilution, SEK		-0.44	-0.21	-1.35	-0.88

Summary consolidated statement of comprehensive income

Amounts in SEK million	2021	2020	2021	2020
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Profit/loss for the period	-26.6	-12.5	-79.9	-44.3
Other comprehensive income				
<i>Items that have been or may be transferred to profit/loss for the period</i>				
Exchange differences on translation of foreign operations	0.0	-	0.0	-
Total comprehensive income for the period after tax	0.0	0.0	0.0	0.0
Total comprehensive income for the period	-26.6	-12.5	-79.9	-44.3
Total comprehensive income for the period attributable to the shareholders of the Parent Company	-26.6	-12.5	-79.9	-44.3

Summary consolidated balance sheet

Amounts in SEK million	Note	Dec 31, 2021	Dec 31, 2020
Assets			
Non-current assets			
Intangible assets		5.5	5.2
Leasehold improvements		7.6	6.5
Plant and equipment		51.0	25.0
Equipment, tools, fixtures and fittings		4.0	2.0
Right-of-use assets		13.7	15.9
Investments in progress		29.2	11.0
Total non-current assets		111.0	65.6
Current assets			
Inventories		21.9	8.4
Trade receivables		4.7	10.1
Other current receivables	3	72.5	6.9
Cash and cash equivalents		28.6	151.9
Total current assets		127.7	177.3
Total assets		238.7	242.9
Equity and liabilities			
Share capital		6.8	6.8
Unregistered share capital		1.9	-
Other contributed capital		407.1	388.5
Retained earnings including profit/loss for the period		-273.3	-193.4
Equity attributable to the Parent Company's shareholders		142.6	201.9
Non-current liabilities			
Lease liabilities		12.1	14.0
Liabilities to credit institutions		3.9	4.6
Total non-current liabilities		16.1	18.6
Current liabilities			
Liabilities to credit institutions		0.7	1.2
Trade payables		15.1	9.6
Other current liabilities		6.0	3.0
Lease liabilities		2.7	2.1
Accrued expenses and deferred income	3	55.5	6.4
Total current liabilities		80.0	22.4
Total equity and liabilities		238.7	242.9

Summary consolidated statement of changes in equity

	2021 Oct-Dec	2020 Oct-Dec	2021 Jan-Dec	2020 Jan-Dec
Amounts in SEK million				
Equity at the beginning of the year	149.2	52.3	201.9	45.1
<i>Total comprehensive income for the year</i>				
Profit/loss for the period	-26.6	-12.5	-79.9	-44.3
Other comprehensive income	0.0	0.0	0.0	-
Total comprehensive income for the period	-26.6	-12.5	-79.9	-44.3
Transactions with the Group's owners				
<i>Contributions by and distributions to owners</i>				
New issue of shares	20.0	175.0	20.0	175.0
New issue expenses	-	-12.9	-	-14.6
Exercising of warrants	-	-	-	38.4
Received option premiums	-0.0	-	0.6	2.3
Exchange differences on translation of foreign operations	0.0	-	0.0	-
Total transactions with the Group's owners	20.0	162.1	20.6	201.1
Closing balance, equity attributable to the Parent Company's shareholders	142.6	201.9	142.6	201.9

Summary consolidated statement of cash flows

	2021 Oct-Dec	2020 Oct-Dec	2021 Jan-Dec	2020 Jan-Dec
Amounts in SEK million				
Operating activities				
Operating result	-25.7	-12.3	-78.0	-43.1
Adjustments for non-cash items	2.9	2.0	10.0	6.7
Net finance income	-0.4	-0.4	-1.3	-1.2
Cash flows from operating activities before changes in working capital	-23.2	-10.6	-69.3	-37.5
Increase (-)/decrease (+) in inventories	0.2	-3.1	-13.6	-6.2
Increase (-)/decrease (+) in operating receivables	-48.7	-12.8	-60.2	-11.3
Increase (+)/decrease (-) in operating liabilities	40.2	4.2	57.1	7.4
Cash flows from operating activities	-31.5	-22.3	-86.1	-47.6
Investing activities				
Acquisition of property, plant and equipment	-15.6	-11.4	-53.0	-22.0
Acquisition of intangible assets	-0.8	-	-1.3	-
Disposals of property, plant and equipment	-	0.1	-	0.1
Cash flows from investing activities	-16.3	-11.3	-54.3	-22.0
Financing activities				
New issue of shares	-	175.0	-	175.0
New issue expenses	-	-12.9	-	-14.6
Premiums received and exercising of warrants	-	-	0.6	40.7
Borrowings	20.0	-	20.0	5.0
Principal elements of lease payments	-0.6	-	-2.4	-
Repayment of borrowings	-0.5	-0.2	-1.2	-1.5
Cash flows from financing activities	18.9	161.9	17.0	204.6
Cash flows for the period	-28.9	128.3	-123.4	134.9
Cash and cash equivalents at the beginning of the period	57.5	23.6	151.9	16.9
Cash and cash equivalents at the end of the period	28.6	151.9	28.6	151.9

Summary Parent Company income statement

	Note	2021 Oct-Dec	2020 Oct-Dec	2021 Jan-Dec	2020 Jan-Dec
Amounts in SEK million					
Net sales		19.0	8.9	71.5	29.3
Changes in inventory and work in progress		1.8	-	10.0	-
Total revenue	2	20.7	8.9	81.5	29.3
Raw materials and consumables		-13.3	-3.2	-46.9	-10.2
Other external costs		-12.0	-7.8	-45.8	-28.1
Staff costs		-19.3	-8.9	-60.5	-28.9
Amortization, depreciation and impairment		-2.1	-1.3	-6.7	-5.1
Other operating costs		-0.0	-0.1	-0.1	-0.2
Operating result		-26.0	-12.4	-79.3	-43.3
Net finance income		-0.6	-0.1	-0.8	-0.2
Profit/loss after financial items		-26.6	-12.5	-79.3	-43.3
Profit/loss before tax		-26.6	-12.5	-79.3	-43.3
Tax		-	-	-	-
Profit/loss for the period		-26.6	-12.5	-79.3	-43.3

Summary Parent Company statement of comprehensive income

	2021 Oct-Dec	2020 Oct-Dec	2021 Jan-Dec	2020 Jan-Dec
Amounts in SEK million				
Profit/loss for the period	-26.6	-12.5	-79.3	-43.3
Other comprehensive income	-	-	-	-
Other comprehensive income for the period after tax	-	-	-	-
Comprehensive income attributable to Parent Company's shareholders	-26.6	-12.5	-79.3	-43.3

Summary Parent Company balance sheet

Amounts in SEK million	Note	Dec 31, 2021	Dec 31, 2020
Assets			
Subscribed capital not paid	3	328.9	-
<i>Non-current assets</i>			
Intangible assets		5.5	5.2
Leasehold improvements		7.6	6.5
Plant and equipment		51.0	25.0
Equipment, tools, fixtures and fittings		4.0	2.0
Investments in progress		29.2	11.0
Participations in Group companies		0.5	0.1
Total non-current assets		97.7	49.7
<i>Current assets</i>			
Inventories		21.9	8.4
Trade receivables		4.7	10.1
Receivables from Group companies		4.1	0
Other current receivables		27.9	7.5
Cash and bank balances		22.9	151.5
Total current assets		81.5	177.5
Total assets		508.0	227.2
Equity and liabilities			
<i>Restricted equity</i>			
Share capital		6.8	6.8
Unregistered share capital		1.9	-
Development expenditure reserve		4.8	5.2
<i>Non-restricted equity</i>			
Share premium reserve		670.4	368.8
Retained earnings		-180.5	-137.4
Profit/loss for the period		-79.3	-43.3
Total equity		424.2	200.0
<i>Non-current liabilities</i>			
Liabilities to credit institutions		3.9	4.6
Liabilities to Group companies		2.5	2.5
Total non-current liabilities		6.4	7.1
<i>Current liabilities</i>			
Liabilities to credit institutions		0.7	1.2
Trade payables		15.1	9.6
Other current liabilities		6.0	3.0
Accrued expenses and deferred income	3	55.6	6.4
Total current liabilities		77.4	20.1
Total equity and liabilities		508.0	227.2

NOTE 1 – ACCOUNTING POLICIES

This year-end report of the Group was prepared in accordance with the Swedish Annual Accounts Act and IAS 34. The Parent Company applies the Swedish Annual Accounts Act and RFR 2. The accounting policies used are consistent with the financial year that ended on December 31, 2020, except for new or revised standards that have been applied as of January 1, 2021. No new IFRS or IFRIC interpretations with application as of 2021 or later are expected to have a material impact on the Group.

NOTE 2 – DISTRIBUTION OF REVENUE

When revenue from external parties is reported to the Management Team, it is measured in the same way as in the consolidated statement of comprehensive income. The majority of revenue is reported at a point in time.

Amounts in SEK million	Group		Parent Company	
	Dec 31, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020
Revenue includes the sale of:				
Goods	81.8	29.3	81.5	29.3
Services	-	-	-	-
Total	81.8	29.3	81.5	29.3
of which revenue from changes in inventory and work in progress	10.0	-	10.0	-

NOTE 3 – ISSUE-RELATED ASSETS AND LIABILITIES

Amounts in SEK million	Dec 31, 2021	Dec 31, 2020
Group		
Issue-related prepaid expenses	45.3	-
Other prepaid expenses (not issue-related)	27.3	6.9
Prepaid expenses	72.5	6.9
Issue-related accrued expenses	42.1	-
Other accrued expenses (not issue-related)	13.4	6.4
Accrued expenses	55.5	6.4
Parent Company		
Issue-related assets	328.9	-
Subscribed capital not paid	328.9	-
Issue-related accrued expenses	42.1	-
Other accrued expenses (not issue-related)	13.5	6.4
Accrued expenses	55.6	6.4

The number of shares as at December 31, 2021 was 75,654,428, of which 16,812,094 shares were subscribed for on December 23, 2021 in connection with the new issue. The new shares were registered at the Swedish Companies Registration Office on January 3, 2022.

The Board of Directors and the CEO affirm that this year-end report provides an accurate overview of the operations, financial position and performance of the Group and the company and describes the significant risks and uncertainties faced by the company.

Karlskoga, February 18, 2022

Robert Sobocki, Chairman

Thomas Carlström

Mikael Eurenius

Anna Frick

Mattias Silfversparre

Pär Teike, CEO

Future set dates for information

Year-end Report 2021	February 18, 2022
Annual Report 2021.....	March 25, 2022
Interim Report, First quarter 2022	May 6, 2022
Interim Report, Second quarter 2022.....	August 25, 2022
Interim Report, Third quarter 2022.....	November 4, 2022
Year-end Report 2022.....	February 17, 2023

Certified Adviser

FNCA Sweden AB (+46 8 528 003 99) has been appointed Certified Adviser for Cell Impact.

This interim report has not been reviewed by the company's auditors.

Cell Impact AB (publ)
Källmossvägen 7A
691 52 Karlskoga, Sweden
Phone: +46 586 574 50
info@cellimpact.com
cellimpact.com

